Developer docs
API playgroundTry for free, no card

Search company profiles

Camurus

Full company profile

uuid0003zr6

Namestring
Camurus
Legal namestring
Camurus AB
Websiteurl
camurus.com
Company typeenum
Public
Founded yearint
1991
Descriptiontext

Camurus AB is a Swedish specialty pharmaceutical company headquartered in Lund that develops and commercializes long-acting injectable medicines for severe and chronic diseases. Its proprietary FluidCrystal technology is a patented lipid-based depot platform that, upon subcutaneous injection, transforms into a liquid crystalline gel to release active substances over days to months via pre-filled syringes or injection pens. The commercial portfolio includes Buvidal (long-acting buprenorphine for opioid dependence, approved in EU/Australia and licensed to Braeburn as Brixadi in the US) and Oczyesa (octreotide SC depot for acromegaly, launched in the EU/UK from November 2025 and filed in the US as Oclaiz).

The company generates revenue through direct specialty sales of approved products across major European markets — supported by wholly-owned subsidiaries in the UK, Germany, Australia, Norway, Finland, Denmark, Austria, Belgium, France, Spain and the US — and through distribution and licensing partnerships that expand geographic reach and monetize the FluidCrystal platform with third-party molecules. Beyond its own products, Camurus pursues a partnered licensing model, most notably with Eli Lilly for long-acting cardiometabolic candidates (GLP-1/GIP/glucagon and amylin receptor agonists) and with Gubra for a long-acting hypoparathyroidism treatment, generating upfronts, milestones and tiered royalties.

FY2025 revenue reached SEK 2,265M (+21% YoY) with profit before tax of SEK 933M (+69% YoY), and FY2026 guidance points to SEK 2.6-2.9B. The pipeline targets indications including acromegaly, gastroenteropancreatic neuroendocrine tumors, polycystic liver disease, hypoparathyroidism, and genetically driven obesity, with a SEK 3.9B cash position at end-Q1 2026 supporting continued investment in organic and partnered R&D.

Short descriptiontext

Camurus AB is a Swedish specialty pharmaceutical company that develops and commercializes long-acting injectable medicines based on its proprietary FluidCrystal depot technology, serving patients with opioid dependence, acromegaly, and other severe chronic diseases across Europe, Australia, and the US.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersLund, Sweden
HQ citystring
Lund
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
long-acting injectables, specialty pharmaceuticals, drug delivery platform, opioid dependence treatment, acromegaly treatment
Industry1 code
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Product Sales
TypeSubscription Recurring
Description

Direct product sales of approved pharmaceuticals including Buvidal (opioid dependence) and Oczyesa (acromegaly, EU/UK). Revenue generated through direct commercial operations in European markets and through distribution partners globally.

news.cision.com
2Partnership Milestones and Royalties
TypeLicensing Royalties
Description

Upfront payments, development and regulatory milestones, sales-based milestones, and tiered royalties from collaboration agreements with pharmaceutical partners including Eli Lilly for FluidCrystal technology licensing.

in.investing.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1FluidCrystal
Description

Proprietary drug delivery technology platform enabling long-acting release of pharmaceuticals from days to months via subcutaneous injection

camurus.com
+3 more records
Core offering1 text field

Camurus develops, manufactures, and commercializes long-acting injectable medicines based on its proprietary FluidCrystal drug delivery technology for severe and chronic diseases. Approved commercial products include Buvidal (long-acting buprenorphine for opioid dependence) and Oczyesa/Oclaiz (octreotide subcutaneous depot for acromegaly). The company also licenses FluidCrystal to partners such as Eli Lilly and Rhythm Pharmaceuticals for cardiometabolic and obesity indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Approximately 5-fold increase in dose-adjusted plasma exposure vs. current approved long-acting intramuscular octreotide
+3 more records
Product and service3 records
1Buvidal
CategorySpecialty pharmaceutical - opioid dependence
Description

Long-acting injectable buprenorphine based on FluidCrystal technology for the treatment of opioid dependence in adults, providing sustained therapeutic effect and reducing dosing frequency to once weekly or monthly subcutaneous administration. Marketed in Europe and Australia.

2Oczyesa (CAM2029)
CategorySpecialty pharmaceutical - endocrinology
Description

Octreotide subcutaneous depot for the treatment of acromegaly, based on FluidCrystal technology. Marketed under the brand name Oczyesa in the EU and UK. Designed for once-monthly subcutaneous self-administration via pre-filled injection pen.

3Oclaiz (CAM2029)
CategorySpecialty pharmaceutical - endocrinology
Description

US brand name for CAM2029 octreotide subcutaneous depot for the treatment of acromegaly, identical formulation to Oczyesa sold in the EU/UK. Pending FDA approval.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

Eli Lilly expanded its collaboration and license agreement with Camurus to include amylin receptor agonists in addition to dual and triple GLP-1/GIP/glucagon receptor agonists. The expanded agreement covers up to four proprietary Lilly drug compounds across three compound classes. Camurus is eligible for up to $290 million in development and regulatory milestones plus $580 million in sales-based milestones, plus tiered mid-single digit royalties on product sales. A $5 million initial payment was triggered by the option exercise.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-16
Description

Exclusive collaboration and license agreement to develop a long-acting treatment for hypoparathyroidism combining Gubra's PTH analogue with Camurus' FluidCrystal technology to enable extended, patient-friendly dosing.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Rights to Brixadi long-acting buprenorphine for treatment of opioid dependence in North America. Brixadi is approved in the USA for opioid use disorder treatment.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Global rights to CAM4072, a weekly formulation of setmelanotide based on FluidCrystal technology, for treatment of genetically driven obesity diseases.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Distribution rights to Buvidal (CAM2038) in twelve countries in the Middle East and North Africa (MENA) region for treatment of opioid dependence.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in GLP-1/diabetes/obesity with deep cardiometabolic pipeline. Comparable given Eli Lilly's amylin/GLP-1 expansion with Camurus targets the same therapeutic class as Novo's pipeline, and Novo is the prior employer of Camurus's new CCDO.

TypeEmerging player
Description

Drug delivery platform company with ENHANZE technology licensed to multiple large pharma partners. Comparable business model of monetizing a proprietary delivery platform through partnerships and royalties across multiple therapeutic areas.

TypeDirect peer
Description

Camurus's own channel partner for Brixadi (long-acting buprenorphine for opioid use disorder) in North America. Direct competitor in the same long-acting depot buprenorphine category with similar delivery dynamics.

TypeEmerging player
Description

Specialty pharma with TransCon technology platform enabling long-acting prodrug injectables for rare endocrine diseases including acromegaly. Highly comparable technology-platform business model targeting overlapping patient populations.

TypeDirect peer
Description

Direct competitor in opioid dependence treatment with Sublocade (long-acting buprenorphine) and Suboxone, the leading therapy franchise in this market. Highly comparable given overlapping patient population, mechanism, and regulatory pathway.

TypeBroad incumbent
Description

Large specialty/generic pharma with broader portfolio including CNS and rare disease assets, plus drug delivery capabilities. Comparable as a broader portfolio player competing in adjacent specialty categories.

TypeBroad incumbent
Description

Privately-held specialty pharma focused on reproductive health, urology, and gastroenterology with strong long-acting injectable expertise (including octreotide franchise competing with Camurus's Oczyesa).

TypeRegional player
Description

Specialty/generic pharma with strong European and MENA presence, including specialty injectable products. Comparable geographic footprint especially given Camurus's NewBridge MENA partnership.

TypeDirect peer
Description

Camurus's partner for CAM4072 (weekly setmelanotide using FluidCrystal) and a developer of rare endocrine/genetic obesity therapies. Direct overlap in rare endocrinology and ongoing collaboration relationship.

TypeBroad incumbent
Description

European specialty pharma with established rare disease and endocrinology franchises. Comparable business model serving similar specialist prescriber base via European commercial infrastructure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries9 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Camurus

Specialty Pharmaceuticalscamurus.com

Camurus AB is a Swedish specialty pharmaceutical company that develops and commercializes long-acting injectable medicines based on its proprietary FluidCrystal depot technology, serving patients with opioid dependence, acromegaly, and other severe chronic diseases across Europe, Australia, and the US.

What Camurus does

Camurus AB is a Swedish specialty pharmaceutical company headquartered in Lund that develops and commercializes long-acting injectable medicines for severe and chronic diseases. Its proprietary FluidCrystal technology is a patented lipid-based depot platform that, upon subcutaneous injection, transforms into a liquid crystalline gel to release active substances over days to months via pre-filled syringes or injection pens. The commercial portfolio includes Buvidal (long-acting buprenorphine for opioid dependence, approved in EU/Australia and licensed to Braeburn as Brixadi in the US) and Oczyesa (octreotide SC depot for acromegaly, launched in the EU/UK from November 2025 and filed in the US as Oclaiz).

The company generates revenue through direct specialty sales of approved products across major European markets — supported by wholly-owned subsidiaries in the UK, Germany, Australia, Norway, Finland, Denmark, Austria, Belgium, France, Spain and the US — and through distribution and licensing partnerships that expand geographic reach and monetize the FluidCrystal platform with third-party molecules. Beyond its own products, Camurus pursues a partnered licensing model, most notably with Eli Lilly for long-acting cardiometabolic candidates (GLP-1/GIP/glucagon and amylin receptor agonists) and with Gubra for a long-acting hypoparathyroidism treatment, generating upfronts, milestones and tiered royalties.

FY2025 revenue reached SEK 2,265M (+21% YoY) with profit before tax of SEK 933M (+69% YoY), and FY2026 guidance points to SEK 2.6-2.9B. The pipeline targets indications including acromegaly, gastroenteropancreatic neuroendocrine tumors, polycystic liver disease, hypoparathyroidism, and genetically driven obesity, with a SEK 3.9B cash position at end-Q1 2026 supporting continued investment in organic and partnered R&D.

Camurus firmographics

Firmographics
Name
Camurus
Legal name
Camurus AB
Website
https://camurus.com
Company type
Public
Founded year
1991
Operating status
Operating
Headcount range
251–500 employees
Short description
Camurus AB is a Swedish specialty pharmaceutical company that develops and commercializes long-acting injectable medicines based on its proprietary FluidCrystal depot technology, serving patients with opioid dependence, acromegaly, and other severe chronic diseases across Europe, Australia, and the US.
Ownership category
akta.pro rank

Camurus industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Long-acting injectables
  • Specialty pharmaceuticals
  • Drug delivery platform
  • Opioid dependence treatment
  • Acromegaly treatment

Where Camurus is headquartered

Location

Headquarters

HQ city
Lund
HQ country
Sweden
HQ region
Europe

Offices5 records

Markets served

Camurus business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. Product Sales: Direct product sales of approved pharmaceuticals including Buvidal (opioid dependence) and Oczyesa (acromegaly, EU/UK). Revenue generated through direct commercial operations in European markets and through distribution partners globally.
  2. Partnership Milestones and Royalties: Upfront payments, development and regulatory milestones, sales-based milestones, and tiered royalties from collaboration agreements with pharmaceutical partners including Eli Lilly for FluidCrystal technology licensing.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Camurus product offering

Product offering

Core offering

Camurus develops, manufactures, and commercializes long-acting injectable medicines based on its proprietary FluidCrystal drug delivery technology for severe and chronic diseases. Approved commercial products include Buvidal (long-acting buprenorphine for opioid dependence) and Oczyesa/Oclaiz (octreotide subcutaneous depot for acromegaly). The company also licenses FluidCrystal to partners such as Eli Lilly and Rhythm Pharmaceuticals for cardiometabolic and obesity indications.

Differentiator

Problem solved

Functional benefit

Brands

  • FluidCrystal: Proprietary drug delivery technology platform enabling long-acting release of pharmaceuticals from days to months via subcutaneous injection
  • Buvidal
  • Oczyesa
  • Oclaiz

Products and services

  • Buvidal Long-acting injectable buprenorphine based on FluidCrystal technology for the treatment of opioid dependence in adults, providing sustained therapeutic effect and reducing dosing frequency to once weekly or monthly subcutaneous administration. Marketed in Europe and Australia.
  • Oczyesa (CAM2029) Octreotide subcutaneous depot for the treatment of acromegaly, based on FluidCrystal technology. Marketed under the brand name Oczyesa in the EU and UK. Designed for once-monthly subcutaneous self-administration via pre-filled injection pen.
  • Oclaiz (CAM2029) US brand name for CAM2029 octreotide subcutaneous depot for the treatment of acromegaly, identical formulation to Oczyesa sold in the EU/UK. Pending FDA approval.

Quantifiable outcome

  • Approximately 5-fold increase in dose-adjusted plasma exposure vs. current approved long-acting intramuscular octreotide
  • +3 more outcomes

Companies that use Camurus

Customer profile

Segments3 records

Ideal customer profiles1 record

Camurus technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Camurus partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and major.

  • Eli LillycoreStrategic or Co-development Partner · 1 June 2026Eli Lilly expanded its collaboration and license agreement with Camurus to include amylin receptor agonists in addition to dual and triple GLP-1/GIP/glucagon receptor agonists. The expanded agreement covers up to four proprietary Lilly drug compounds across three compound classes. Camurus is eligible for up to $290 million in development and regulatory milestones plus $580 million in sales-based milestones, plus tiered mid-single digit royalties on product sales. A $5 million initial payment was triggered by the option exercise.
  • GubracoreStrategic or Co-development Partner · 16 December 2025Exclusive collaboration and license agreement to develop a long-acting treatment for hypoparathyroidism combining Gubra's PTH analogue with Camurus' FluidCrystal technology to enable extended, patient-friendly dosing.
  • BraeburnmajorChannel Partner/ Reseller/ DistributorRights to Brixadi long-acting buprenorphine for treatment of opioid dependence in North America. Brixadi is approved in the USA for opioid use disorder treatment.
  • Rhythm PharmaceuticalsmajorStrategic or Co-development PartnerGlobal rights to CAM4072, a weekly formulation of setmelanotide based on FluidCrystal technology, for treatment of genetically driven obesity diseases.
  • NewBridge PharmaceuticalsmajorChannel Partner/ Reseller/ DistributorDistribution rights to Buvidal (CAM2038) in twelve countries in the Middle East and North Africa (MENA) region for treatment of opioid dependence.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Camurus competitors and assessment

Company assessment

Broad incumbents

  • Novo Nordisk: Global leader in GLP-1/diabetes/obesity with deep cardiometabolic pipeline. Comparable given Eli Lilly's amylin/GLP-1 expansion with Camurus targets the same therapeutic class as Novo's pipeline, and Novo is the prior employer of Camurus's new CCDO.
  • Teva Pharmaceutical Industries: Large specialty/generic pharma with broader portfolio including CNS and rare disease assets, plus drug delivery capabilities. Comparable as a broader portfolio player competing in adjacent specialty categories.
  • Ferring Pharmaceuticals: Privately-held specialty pharma focused on reproductive health, urology, and gastroenterology with strong long-acting injectable expertise (including octreotide franchise competing with Camurus's Oczyesa).
  • Recordati S.p.A. European specialty pharma with established rare disease and endocrinology franchises. Comparable business model serving similar specialist prescriber base via European commercial infrastructure.

Emerging players

  • Halozyme Therapeutics: Drug delivery platform company with ENHANZE technology licensed to multiple large pharma partners. Comparable business model of monetizing a proprietary delivery platform through partnerships and royalties across multiple therapeutic areas.
  • Ascendis Pharma: Specialty pharma with TransCon technology platform enabling long-acting prodrug injectables for rare endocrine diseases including acromegaly. Highly comparable technology-platform business model targeting overlapping patient populations.

Direct peers

  • Braeburn Pharmaceuticals: Camurus's own channel partner for Brixadi (long-acting buprenorphine for opioid use disorder) in North America. Direct competitor in the same long-acting depot buprenorphine category with similar delivery dynamics.
  • Indivior PLC: Direct competitor in opioid dependence treatment with Sublocade (long-acting buprenorphine) and Suboxone, the leading therapy franchise in this market. Highly comparable given overlapping patient population, mechanism, and regulatory pathway.
  • Rhythm Pharmaceuticals: Camurus's partner for CAM4072 (weekly setmelanotide using FluidCrystal) and a developer of rare endocrine/genetic obesity therapies. Direct overlap in rare endocrinology and ongoing collaboration relationship.

Regional players

  • Hikma Pharmaceuticals: Specialty/generic pharma with strong European and MENA presence, including specialty injectable products. Comparable geographic footprint especially given Camurus's NewBridge MENA partnership.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Camurus social profiles

Digital presence

Camurus financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Camurus leadership team

Management profile

Number of profiles

Profiles6 records

Camurus subsidiaries and ownership

Company hierarchy

Subsidiaries9 records

Camurus funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Camurus M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Camurus

What does Camurus do?

Camurus develops, manufactures, and commercializes long-acting injectable medicines based on its proprietary FluidCrystal drug delivery technology for severe and chronic diseases. Approved commercial products include Buvidal (long-acting buprenorphine for opioid dependence) and Oczyesa/Oclaiz (octreotide subcutaneous depot for acromegaly). The company also licenses FluidCrystal to partners such as Eli Lilly and Rhythm Pharmaceuticals for cardiometabolic and obesity indications.

Is Camurus a public or private company?

Camurus is a public company. It is classified as public and is currently operating.

When was Camurus founded?

Camurus was founded in 1991. It employs 251 to 500 people.

Where is Camurus based?

Camurus is headquartered in Lund, Sweden, in the Europe region.

How does Camurus make money?

Two revenue lines are on record. Product Sales are the primary driver. The others are partnership Milestones and Royalties.

Who are Camurus's main competitors?

Broad incumbents on record are Novo Nordisk, Teva Pharmaceutical Industries, Ferring Pharmaceuticals and Recordati S.p.A.. Emerging players are Halozyme Therapeutics and Ascendis Pharma. Direct peers are Braeburn Pharmaceuticals, Indivior PLC and Rhythm Pharmaceuticals. Hikma Pharmaceuticals is listed as a regional player.

Does Camurus have an API?

No public API is recorded for Camurus.

What industry is Camurus in?

Camurus's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewCAMX: Opioid growth and 2027 pipeline catalysts underpin the next expansion phaseCamurus AB's growth is led by opioid dependence treatments, with 2027 contributions expected from market expansion and acromegaly launches. SorenTO results are expected in 1Q 2027, and CAM2056 phase IIb data are due in 1H 2028.Investing.comCamurus at Jefferies Global Healthcare Conference: growth and catalystsCamurus reported its strongest quarter to date at the Jefferies Global Healthcare Conference, with robust revenue growth and operating profit. The company holds 4.4 billion Swedish crowns in cash and no debt, and Buvidal is on track to treat 100,000 patients by end of 2026. The SORENTO Phase III readout for CAM2029 is expected in Q1 2027.Business & FinancialNeuroendocrine Tumors Clinical Trials Update 2026: Phase-Wise Pipeline Status, Drug Profiles, And Key Developers Camurus, Orano Med, Vyriad, Pfizer, Takeda Oncology, Hutchison Medipharma, ProvectusDelveInsight's 2026 Neuroendocrine Tumors pipeline report profiles therapies from Camurus, Orano Med, and others. The FDA approved BRAVNETSA and BEXLUTRY in September 2026, and ITM's Phase III COMPETE trial showed ITM-11 improved progression-free survival versus everolimus.news.cision.comCamurus to present at Jefferies Global Healthcare ConferenceCamurus will present at the Jefferies Global Healthcare Conference in London on 16–19 November, with CEO Fredrik Tiberg speaking on 18 November. The presentation will be available via webcast. The company develops long-acting medicines for chronic diseases using its FluidCrystal technology.news.cision.comIHE and Camurus study indicates substantial societal cost reductions associated with opioid dependence treatment in the UKA study by Camurus and IHE estimated that each person with opioid dependence retained in treatment for one year reduces societal costs by GBP 140,876 compared with no treatment. Most savings come from families, communities, productivity, and criminal justice, not healthcare. The findings support cross-sector policy and funding decisions.Simply Wall StCamurus AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their PredictionsCamurus reported revenues of kr724m, beating expectations by 3.7%, and statutory profit of kr4.53, 25% above forecasts. Analysts reconfirmed 2027 revenue of kr3.68b and EPS of kr23.68, with a price target of kr832. The company is expected to grow faster than its industry.Seeking AlphaCamurus AB (publ) (CAMRF) Q3 2026 Earnings Call TranscriptCamurus reported Q3 2026 revenue of SEK 724 million, up 28%, and an operating result of SEK 322 million, up 40%. The company ended the quarter with SEK 4.4 billion in cash and no debt, driven by record product sales and strong commercial execution.Dagens industriBörsen på rekordnivå – Yubico och Camurus rapportrusarStockholm stock exchange is trading at record levels, with the broad OMXSPI index up 0.8% and the OMXS30 up 0.6% as of the latest data. The market is expected to remain upbeat on Thursday.Dagens industriCamurus vd: Det ska kassan användas tillCamurus reported nearly 4.4 billion kronor in cash at the end of Q3 2026. The funds will be used for upcoming launches, new clinical projects, business development, and possible acquisitions.AffarsvarldenCamurus ökar vinsten med 40%Camurus reported Q3 revenue up 28% to 724 million SEK, with operating profit up 40% to 322 million SEK. Net profit rose 40% to 270 million SEK, and EPS after dilution was 4.53 kronor. The company reaffirmed its full-year revenue forecast of 2.6–2.9 billion SEK.